Episode 047: This is a guideline shredding study. This landmark study of blood pressure in pregnancy is going to change how we approach hypertension in pregnancy.
Freely Filtered does TESTING-2
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because of excess adverse events to a safe and effective therapy with just a few tweeks. Amazing turn around. Join the Filtrate as we put TESTING to the test with study author Sean Barbour.
Freely Filtered does SODIUM-HF
Episode 049: SODIUM-HF is the largest and longest RCT done looking at sodium restriction heart failure. The top line results show no effect but the more you look at the study the more problematic it is. The Filtrate take it to task.
Freely Filtered does The Classic Trial
Freely Filtered 050: CLASSIC Trial. The Filtrate look at the latest contribution to Fluid Wars, this one looking at late resuscitation.
Freely Filtered does Pip/Tazo and Vanco. Toxin or pseudotoxin?
The Filtrate looks at a trial that tries to dissect the bumps in creatinine we regularly see with Pip/Tazo. Is it AKI or pseudonephrotoxicity?
Freely Filtered does ADVOR
ADVOR turns the practice of sequential nephron blockade on its head by blocking the proximal tubule before the loop of Henle. Does it work? Join The Filtrate as we dissect the latest diuretic RCT.
Freely Filtered does EMPA-Kidney
Freely Filtered 054: EMPA-Kidney. EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that had previously been unanswered. Join the Filtrate as they tear it apart.
MyTEMP Visual Abstract
When feeling cool isn’t cool: the MyTEMP trial
New player in resistant hypertension?
This week we discussed aprocitentan, another endothelin receptor antagonist, this time being explored in the resistant hypertension arena - you know the #TenTweetNephJC drill, if you want a rapid catch up then here’s your place!
PRECISION Targeting in Resistant Hypertension
The PRECISION Visual Abstract
Is Aprocitentan effective in lowering BP in resistant hypertension? PRECISION trial answers it with a meticulous design. Checkout the VA by NSMC intern Sandhya Suresh which captures many elements of that meticulous design.
Another EMPA-Kidney Tweetorial
Friend of NephJC, Daniel Schwartz does a nice tweetorial on EMPA-Kidney
Don't Stop Me Now!
If you missed the latest NephJC discussion, at least read the highlights here.
You gotta know when to hold’em and know when to fold’em. Review the #TenTweetNephJC for the STOP ACEi Trial, and always hold onto your ACEi.
So where is the gift I was promised for donating to NephJC?
Use @CaptainChloride's tweetorial to prep for tonight's NephJC
TESTING 2.0 in Kidney Medicine
The NephJC editorial in Kidney Medicine is live. Great work from Anand Chellapan and Rachael Kermond, supported by Tiffany, Jade and Swap. Read it here.
With a bonus table which already needs updating post EMPAKIDNEY!
Keep Calm and Carry on Inhibiting the RAS
The STOP ACEi Trial - Visual Abstract
Does the discontinuation of RAS inhibitors improve eGFR in patients with advanced CKD? NSMC Intern Dana Larsen explains it graphically.
